Project Grant DP2DA063114
Award Date
7/1/25
Completion Date
6/30/29
Dollars Obligated
$2.4M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to design tailored harm reduction strategies to address the escalating drug overdose crisis in the United States. The $2,316,128 award, with a project period from September 15, 2024 to July 31, 2028, will support collaborative efforts with health departments and community partners across six jurisdictions (Rhode Island, Massachusetts, New York...
This $3,067,394 Project Grant from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a 2-year research study to test a peer-driven "intravention" approach to address unmet harm reduction needs among people who use drugs in two rural Kentucky counties. The project, titled "Engaging People Who Use Drugs in Harm Reduction Service Delivery", aims to reduce the risk of overdose, hepatitis C, skin/soft tissue...
This $1,192,612 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD). The key objectives are to: 1) conduct a systematic assessment of healthcare utilization, HIV prevention services, and medication for OUD (MOUD) using claims and emergency department data; 2) use an evidence-based quality improvement...
The federal Project Grant award with ID DP2DA062283 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $2,542,500 grant, awarded on September 1, 2024, will support the development of novel econometric methods and a unified framework for integrating real-world evidence (RWE) to analyze inconclusive randomized controlled trials (RCTs) focused on opioid use disorder (OUD) treatments. The project, to be conducted by Weill...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,607,146 Project Grant to Ndri-Usa Inc., a non-profit organization based in New York City. The grant, titled "TOGETHER AGAINST OVERDOSE: COMMUNITY DEVELOPED TECHNOLOGY TO ENCOURAGE DRUG CHECKING, DISTRIBUTION OF HARM REDUCTION SUPPLIES, AND LINKAGE TO SERVICES", aims to develop technology-based interventions to increase protective behaviors against overdose, such...
The National Institute on Drug Abuse (NIDA) awarded a $1,994,766 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Cambridge Public Health Commission, doing business as Cambridge Health Alliance (CHA), to assess the causal impact and equity effects of the New York State Medicaid Value-Based Payment (VBP) policy on opioid use disorder (OUD)-related outcomes. The key products and services to be delivered under this 2-year grant, which begins on August 1, 2024,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $157,684 to New York University (NYU) to conduct research on understanding inequities in harm reduction services provided to persons with opioid use disorder in hospital settings. The study will use natural language processing (NLP) and electronic health record (EHR) data to characterize providers' recommendations of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,332,500 to the University of Washington to build a learning health system across Washington's state prisons. The project aims to: Establish the foundation for a learning health system, including quality metrics and a patient advisory board. Define gaps in access to care for conditions like HIV, hepatitis C, and substance use disorders by...
The J. David Gladstone Institutes received a $687,416 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research aimed at developing latency-promoting agents (LPAs) that can suppress the HIV transcriptionally active reservoir and lock HIV in a silenced state, even in the presence of addictive substances. The research combines expertise in HIV biology and targeted kinase inhibition to advance...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $234,000 to Georgetown University to conduct research on the effect of opioids on HIV transcription and latency. The key objectives are to understand the mechanisms by which opioids like fentanyl, morphine, and methadone influence HIV proviral transcription in microglia and astrocytes, and to use a novel dual fluorescent and bioluminescent virus to...